NI201200084A - Derivados de sulfonamidas heterocíclicos útiles como inhibidores de mek - Google Patents

Derivados de sulfonamidas heterocíclicos útiles como inhibidores de mek

Info

Publication number
NI201200084A
NI201200084A NI201200084A NI201200084A NI201200084A NI 201200084 A NI201200084 A NI 201200084A NI 201200084 A NI201200084 A NI 201200084A NI 201200084 A NI201200084 A NI 201200084A NI 201200084 A NI201200084 A NI 201200084A
Authority
NI
Nicaragua
Prior art keywords
useful
derivatives
mek inhibitors
sulphonamides
heterocyclic
Prior art date
Application number
NI201200084A
Other languages
English (en)
Inventor
G Bock Mark
Mccarthy Clive
Chikkanna Dinesh
Moebitz Henrik
Pandit Chetan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43416908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201200084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI201200084A publication Critical patent/NI201200084A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (IA): en donde R1a, R1b, X, R2a, R2b, W, R3, R4, y R5 son como se definen en la presente, así como a las sales farmacéuticamente aceptables de los mismos. Se ha demostrado que los compuestos actúan como inhibidores de MEK, lo cual puede ser útil en el tratamiento de enfermedades hiperproliferativas, como cáncer e inflamación.
NI201200084A 2009-11-04 2012-05-03 Derivados de sulfonamidas heterocíclicos útiles como inhibidores de mek NI201200084A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2678CH2009 2009-11-04

Publications (1)

Publication Number Publication Date
NI201200084A true NI201200084A (es) 2012-08-13

Family

ID=43416908

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200084A NI201200084A (es) 2009-11-04 2012-05-03 Derivados de sulfonamidas heterocíclicos útiles como inhibidores de mek

Country Status (30)

Country Link
US (1) US8466289B2 (es)
EP (1) EP2496575B1 (es)
JP (1) JP5466767B2 (es)
KR (1) KR101398772B1 (es)
CN (1) CN102596951B (es)
AR (1) AR078900A1 (es)
AU (1) AU2010317167B2 (es)
BR (1) BR112012010519A2 (es)
CA (1) CA2779935A1 (es)
CL (1) CL2012001027A1 (es)
CO (1) CO6541547A2 (es)
CR (1) CR20120234A (es)
DO (1) DOP2012000127A (es)
EA (1) EA201200651A1 (es)
EC (1) ECSP12011878A (es)
ES (1) ES2487628T3 (es)
GT (1) GT201200138A (es)
IL (1) IL219113A0 (es)
MA (1) MA33721B1 (es)
MX (1) MX2012005293A (es)
MY (1) MY156209A (es)
NI (1) NI201200084A (es)
NZ (1) NZ599565A (es)
PE (1) PE20121471A1 (es)
PH (1) PH12012500823A1 (es)
TN (1) TN2012000153A1 (es)
TW (1) TW201139449A (es)
UY (1) UY33000A (es)
WO (1) WO2011054828A1 (es)
ZA (1) ZA201202530B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012265844A1 (en) * 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
US10398696B2 (en) 2013-03-12 2019-09-03 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combinations for treatment of cancer
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106518885B (zh) * 2016-10-26 2018-10-16 云南大学 1,3-二氮杂环并吡啶季铵盐类化合物及其中间体化合物、制备方法和应用
JP7303205B2 (ja) * 2018-02-12 2023-07-04 アレイ・バイオファーマ・インコーポレーテッド 胆道癌を処置するための方法および併用療法
US11723891B2 (en) 2018-04-12 2023-08-15 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of RAS-mutant cancer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111548344B (zh) * 2020-06-10 2025-01-28 北京深度制耀科技有限公司 Stat3小分子抑制剂及其应用
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN119528775A (zh) * 2024-08-05 2025-02-28 瑞博(苏州)制药有限公司 一种含环丁基的丙酸甲酯及丙二醇衍生物的合成方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
AU2912997A (en) 1996-06-24 1998-01-14 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
CA2264908C (en) 1996-09-06 2006-04-25 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BR0116539A (pt) 2000-12-28 2003-09-23 Shionogi & Co Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8648116B2 (en) 2005-07-21 2014-02-11 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CA2649122C (en) 2006-04-18 2015-06-30 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
MX2009007661A (es) * 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
PE20090286A1 (es) 2007-05-11 2009-03-27 Bayer Schering Pharma Ag Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitogenos
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
AR071587A1 (es) 2008-04-21 2010-06-30 Novartis Ag Compuestos heterociclicos como inhibidores de mek
US20110039819A1 (en) 2008-04-22 2011-02-17 Marion Hitchcock Substituted phenoxybenzamides
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
UY32486A (es) 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
AU2009344690A1 (en) * 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors

Also Published As

Publication number Publication date
AU2010317167A1 (en) 2012-05-03
JP2013510118A (ja) 2013-03-21
KR20120090078A (ko) 2012-08-16
CO6541547A2 (es) 2012-10-16
EA201200651A1 (ru) 2012-12-28
TN2012000153A1 (en) 2013-12-12
ZA201202530B (en) 2013-01-30
UY33000A (es) 2011-06-30
ECSP12011878A (es) 2012-07-31
AU2010317167B2 (en) 2012-11-29
DOP2012000127A (es) 2012-08-31
PE20121471A1 (es) 2012-11-01
MY156209A (en) 2016-01-29
PH12012500823A1 (en) 2013-01-07
CL2012001027A1 (es) 2012-08-03
MA33721B1 (fr) 2012-11-01
KR101398772B1 (ko) 2014-05-27
TW201139449A (en) 2011-11-16
ES2487628T3 (es) 2014-08-22
EP2496575B1 (en) 2014-04-30
NZ599565A (en) 2013-05-31
WO2011054828A1 (en) 2011-05-12
EP2496575A1 (en) 2012-09-12
CA2779935A1 (en) 2011-05-12
BR112012010519A2 (pt) 2017-12-05
CN102596951A (zh) 2012-07-18
US8466289B2 (en) 2013-06-18
CN102596951B (zh) 2015-04-15
AR078900A1 (es) 2011-12-14
US20110190334A1 (en) 2011-08-04
JP5466767B2 (ja) 2014-04-09
GT201200138A (es) 2014-03-27
IL219113A0 (en) 2012-06-28
MX2012005293A (es) 2012-06-19
CR20120234A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
NI201200084A (es) Derivados de sulfonamidas heterocíclicos útiles como inhibidores de mek
UY33227A (es) Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
ECSP088456A (es) Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias
MX2019010602A (es) Inhibidores de cdk.
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
UY35395A (es) Inhibidores de bromodominios tetracíclicos
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
UY33430A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
NI201200100A (es) Derivados de sulfonamida heterocíclicos
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CR20150148A (es) Azaindolinas
EA201391820A1 (ru) Гетероциклические сульфонамидные производные
AR086876A1 (es) Derivados heterociclicos de sulfonamida
CU20120067A7 (es) Derivados de sulfamida heterocíclicos y su uso como inhibidores de mek
CY1114907T1 (el) N1-πυραζολοσπειροκετονης αναστολεις ακετυλ-coa καρβοξυλασης
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP11011535A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus